Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Taps Mosaic to Develop Reimbursement Plan for Ovarian Cancer Dx

NEW YORK (GenomeWeb News) - Mosaic Health Care Consultants has agreed to develop reimbursement strategies and programs for Ciphergen Biosystems' ovarian cancer test, Ciphergen said yesterday. 
 
Ciphergen's ovarian cancer triage test, which the company plans to submit for FDA approval after it completes clinical trials, uses a biomarker panel to measure risk stratification.
 
Ciphergen president and CEO Gail Page said in a statement that developing a reimbursement plan is for the test is "one crucial aspect of gaining rapid adoption by the medical community."
 
Earlier this week, the company said it had hired the consulting company Emergo to help it gain European CE Mark clearance for the test.
 
Ciphergen has an existing agreement with Quest Diagnostics to commercialize the biomarker-based test after FDA approval.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.